Skip to main content
SpringerLink
Log in

Imatinib Cardiotoxicity

  • Chapter
  • First Online:
Clinical Cases in Cardio-Oncology

Part of the book series: Clinical Cases in Cardiology ((CCC))

  • 327 Accesses

Abstract

Patient was a 65-year-old female presented to the emergency department with an episode of palpitation, peripheral edema, shortness of breath and mild increase in troponin. She was known for CML on imatinib treatment. Her ECG on presentation to the hospital showed regular narrow complex tachycardia with heart rate of 160 bpm, RP interval more than PR interval. Echocardiogram showed LV ejection fraction of 45% with basal inferior and basal inferoseptal wall hypokinesia. It was difficult to conclude these cardiovascular complications was imatinib related or a process of aging and atherosclerosis, however underlying myocardial dysfunction could be exacerbated by imatinib in this patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer. 2007;43(6):974–8.

    Article  CAS  Google Scholar 

  2. Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233–7.

    Article  CAS  Google Scholar 

  3. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004;9(3):271–81.

    Article  CAS  Google Scholar 

  4. Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–16.

    Article  Google Scholar 

  5. Hatfield A, Owen S, Pilot PR. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med. 2007;13(1):13. Author reply 15-6. PMID: 17206118. https://doi.org/10.1038/nm0107-13a.

    Article  CAS  PubMed  Google Scholar 

  6. Mann DL. Targeted cancer therapeutics: the heartbreak of success. Nat Med. 2006;12(8):881–2. https://doi.org/10.1038/nm0806-881. PMID: 16892027.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northern Ontario School of Medicine, Thunder Bay, ON, Canada

    Atooshe Rohani

Authors
  1. Atooshe Rohani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atooshe Rohani .

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Rohani, A. (2021). Imatinib Cardiotoxicity. In: Clinical Cases in Cardio-Oncology. Clinical Cases in Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-71155-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-71155-9_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-71154-2

  • Online ISBN: 978-3-030-71155-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation